📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. (2022)

First Author: Badodi S

Attributed to: A BMI1/CHD7 signature in medulloblastoma with poor prognosis. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/neuonc/noac052

PubMed Identifier: 35213723

Publication URI: http://europepmc.org/abstract/MED/35213723

Type: Journal Article/Review

Volume: 24

Parent Publication: Neuro-oncology

Issue: 8

ISSN: 1522-8517